Fate Therapeutics Inc (FATE) - Total Liabilities
Based on the latest financial reports, Fate Therapeutics Inc (FATE) has total liabilities worth $109.61 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore FATE operating cash flow to assess how effectively this company generates cash.
Fate Therapeutics Inc - Total Liabilities Trend (2011–2024)
This chart illustrates how Fate Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. Check FATE asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Fate Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Fate Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Korea Fuel-Tech Corporation
KQ:123410
|
Korea | ₩247.50 Billion |
|
Mercuries Data Systems Ltd
TW:2427
|
Taiwan | NT$3.46 Billion |
|
Soosan Heavy I
KO:017550
|
Korea | ₩77.87 Billion |
|
Bonus Biogroup
TA:BONS
|
Israel | ILA19.00 Million |
|
CPE Technology Berhad
KLSE:5317
|
Malaysia | RM23.34 Million |
|
Lara Exploration Ltd.
V:LRA
|
Canada | CA$266.12K |
|
Fabryki Mebli Forte S.A.
WAR:FTE
|
Poland | zł453.37 Million |
|
Dong Hai JSC of Bentre
VN:DHC
|
Vietnam | ₫1.37 Trillion |
Liability Composition Analysis (2011–2024)
This chart breaks down Fate Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Fate Therapeutics Inc (FATE) market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 7.87 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.47 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.32 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Fate Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Fate Therapeutics Inc (2011–2024)
The table below shows the annual total liabilities of Fate Therapeutics Inc from 2011 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $121.97 Million | -11.49% |
| 2023-12-31 | $137.80 Million | -37.82% |
| 2022-12-31 | $221.62 Million | -8.65% |
| 2021-12-31 | $242.62 Million | +1.93% |
| 2020-12-31 | $238.01 Million | +313.80% |
| 2019-12-31 | $57.52 Million | +9.43% |
| 2018-12-31 | $52.56 Million | +87.04% |
| 2017-12-31 | $28.10 Million | +28.36% |
| 2016-12-31 | $21.89 Million | -26.82% |
| 2015-12-31 | $29.92 Million | +30.86% |
| 2014-12-31 | $22.86 Million | +382.87% |
| 2013-12-31 | $4.74 Million | -92.59% |
| 2012-12-31 | $63.90 Million | +9.17% |
| 2011-12-31 | $58.53 Million | -- |
About Fate Therapeutics Inc
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma; FT836 whiuch is in preclinical stage for multiple tumor types; and FT522, to treat… Read more